Log in

LON:N4P - N4 Pharma Share Price, Forecast & News

GBX 3.15
0.00 (0.00 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
Now: GBX 3.15
50-Day Range
MA: GBX 3.14
52-Week Range
Now: GBX 3.15
Volume738,531 shs
Average Volume1.76 million shs
Market Capitalization£3.20 million
P/E RatioN/A
Dividend YieldN/A
N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs; and improves delivery of novel and existing vaccines and therapeutics. The company is developing Sildenafil for use in treating erectile dysfunction; Sartans for the treatment of hypertension; Aprepitant for use in oncology and pain relief; and Aprepitant for the treatment of premature ejaculation. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Major



Sales & Book Value

Annual Sales£23,524.00
Cash FlowGBX 1.16 per share
Book ValueGBX 1.30 per share



Market Cap£3.20 million
Next Earnings DateN/A
OptionableNot Optionable

Receive N4P News and Ratings via Email

Sign-up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter.

N4 Pharma (LON:N4P) Frequently Asked Questions

What is N4 Pharma's stock symbol?

N4 Pharma trades on the London Stock Exchange (LON) under the ticker symbol "N4P."

Has N4 Pharma been receiving favorable news coverage?

Headlines about N4P stock have been trending negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. N4 Pharma earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the near term. View News Stories for N4 Pharma.

Who are some of N4 Pharma's key competitors?

What other stocks do shareholders of N4 Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other N4 Pharma investors own include Medpace (MEDP), Sirius Minerals (SXX), SolGold (SOLG), Petra Diamonds (PDL), Interserve (IRV), Intercede Group (IGP), Bushveld Minerals (BMN) and Cornerstone Capital Resources (CGP).

Who are N4 Pharma's key executives?

N4 Pharma's management team includes the folowing people:
  • Mr. Nigel James Theobald, Founder & CEO (Age 55)
  • Mr. Paul Titley, Exec. Director
  • Dr. Andrew Leishman, Consultant

How do I buy shares of N4 Pharma?

Shares of N4P and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is N4 Pharma's stock price today?

One share of N4P stock can currently be purchased for approximately GBX 3.15.

How big of a company is N4 Pharma?

N4 Pharma has a market capitalization of £3.20 million and generates £23,524.00 in revenue each year. N4 Pharma employs 5 workers across the globe.View Additional Information About N4 Pharma.

What is N4 Pharma's official website?

The official website for N4 Pharma is http://www.n4pharma.com/.

How can I contact N4 Pharma?

N4 Pharma's mailing address is Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom. The company can be reached via phone at +44-1332-690061.

MarketBeat Community Rating for N4 Pharma (LON N4P)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  208
MarketBeat's community ratings are surveys of what our community members think about N4 Pharma and other stocks. Vote "Outperform" if you believe N4P will outperform the S&P 500 over the long term. Vote "Underperform" if you believe N4P will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel